DAVID LEE JOHNSON - 01 Sep 2021 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role: Chief Commercial Officer
Signature: /s/ Miguel Carrillo, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Sep 2021
Net transactions value: -$20,292
Form type: 4
Filing time: 03 Sep 2021, 20:01:07 UTC
Previous filing: 24 Sep 2021
Next filing: 05 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GBT	Common Stock	Award	$11,707	+480	+1.4%	$24.39	35,177	31 Aug 2021	Direct	F1
transaction	GBT	Common Stock	Options Exercise		+2,762	+7.9%		37,939	01 Sep 2021	Direct	F2
transaction	GBT	Common Stock	Tax liability	$31,999	-1,072	-2.8%	$29.85	36,867	01 Sep 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GBT	Restricted Stock Units	Options Exercise	$0	-2,762	-12%	$0.000000	19,340	01 Sep 2021	Common Stock	2,762		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2	Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F3	Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,762 shares of Common Stock underlying the Reporting Person's RSUs.
F4	The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.